Comparison Between Calculated Bioavailable Testosterone Level With Radio-immunoassay Result.

NCT04807231 | Completed

• 1 other identifier: PI2021_843_0044
• Study Type: observational
• Target: 270
• Locations: 1 country
• Sites: 1

Brief Summary

Currently, the gold standard to obtain bioavailable testosterone results is radioimmunoassay (RIA). However, this assay requires specific equipment. Giton in 2006 proposed an optimized calculation of the Vermeulen equation, the results of which seem to be well correlated with those obtained by RIA. The aim of this study is to determine if the bioavailable testosterone levels determined by both methods are similar in order to replace the usual RIA assay of bioavailable testosterone by this calculation.

Conditions

Testosterone; Androgens

Keywords

testosterone; androgens; men; women

Outcome Measures

Primary Outcomes (1)

• Concordance between RIA and calculated testosterone level

  Concordance between RIA and calculated testosterone level

  2 years

Interventions

Blood withdrawal BIOLOGICAL

Blood withdrawal in order to perform a bioavailable testosterone RIA (Radio-Immuno Assay).

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The population of this study is a unique cohort of 270 patients, male and female, aged between 18 and 90 (included). These patients have been included if there were being prescribed bioavailable testosterone by their physician in routine.

You may qualify if:

• Every men and women aged between 18 and 90 can be included

You may not qualify if:

• insufficient sample
• sample not send for RIA

Sponsors & Collaborators

• Centre Hospitalier Universitaire, Amiens: lead

Study Sites (1)

CHU Amiens

Amiens, 80480, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood sample in order to perform a bioavailable testosterone Radio-Immuno Assay

MeSH Terms

Conditions

Multiple Endocrine Neoplasia Type 1

Condition Hierarchy (Ancestors)

Multiple Endocrine Neoplasia; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Neoplasms, Multiple Primary; Neoplastic Syndromes, Hereditary; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Endocrine System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 11, 2021
• First Posted: March 19, 2021
• Study Start: February 19, 2021
• Primary Completion: February 18, 2023
• Study Completion: February 18, 2023
• Last Updated: June 12, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)